Introduction {#Sec1}
============

Sepsis and septic shock still represent major health issues, with persisting high morbidity and mortality rates in critically ill patients. Cardiac dysfunction\[[@CR1]\] occurs frequently during severe sepsis.

Adrenomedullin (ADM) has been identified as a key mediator in vascular tone regulation\[[@CR1]\]. A newly developed anti-ADM antibody Adrecizumab (ADZ) may improve hemodynamic dysfunction during resuscitated murine, cecal ligation and puncture (CLP)-induced septic shock\[[@CR2]\].

Objectives {#Sec2}
==========

To determine the beneficial role of ADZ on hemodynamic impairment in a rat model of acute sepsis.

Methods {#Sec3}
=======

For induction of polymicrobial sepsis, cecal ligation and puncture (CLP)\[[@CR3]\] was performed in Wistar male rats. ADZ (2 mg/kg) was injected IV 24 h after the surgery. There were 7 animals per group. Invasive blood pressure and cardiac function (by echocardiography) were assessed until 2 hours after ADZ injection. Statistical analysis was performed with 2 ways ANOVA.

Results {#Sec4}
=======

Septic rats had lower mean arterial pressure (MAP) (*p* \< 0.0001) 24 h after surgery (at baseline) compared to sham. Septic animas with ADZ had a trend to have a greater MAP. A transient decrease of SF was observed 15 min and 1 h after injection of ADZ (*p* = 0.05). On the other hand cardiac output seems to be increased by ADZ (*p* = 0.61).

Conclusions {#Sec5}
===========

During sepsis in rats, treatment by ADZ seems to have a beneficial effect on cardiac and vascular dysfunction. These preliminary results need to be confirmed in preclinical and clinical studies.Figure 1***\[Mean arterial pressure\]***
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